1,25-Dihydroxyvitamin D3 Enhances the Expression of Transforming Growth Factor 01 and Its Latent Form Binding Protein in Cultured Breast Carcinoma Ceils

Cancer Research

Volumn 55, Issue 7, 1995, Pages 1540-1546

  Koli, Katri ^a   Keski Oja, Jorma ^b  

^a Departments of Virology and of Dermatology and Venereology ^*  (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CALCIPOTRIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CYCLOHEXIMIDE; DACTINOMYCIN; ESTROGEN RECEPTOR; LEXACALCITOL; MESSENGER RNA; POLYCLONAL ANTIBODY; SEOCALCITOL; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL GROWTH; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; GENE INDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; RNA SYNTHESIS;

BREAST NEOPLASMS; CALCITRIOL; CARRIER PROTEINS; CYCLOHEXIMIDE; DACTINOMYCIN; HUMAN; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0028987267     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Walters, M.R. Newly identified actions of the vitamin D endocrine system. Endocr. Rev. 13: 719-764, 1992.
2. Sandgren, M. Danforth, L. Plasse, T.F. and DeLuca, H.F. 1, 25-Dihydroxyvitamin D3 receptors in human carcinomas: a pilot study. Cancer Res. 51: 2021-2024, 1991.
3. Bikle, D.D. Clinical counterpoint: Vitamin D: new actions, new analogs, new therapeutic potential. Endocr. Rev. 13: 765-784, 1992.
4. Veyron, P. Pamphile, R. Binderup, L. and Touraine, J.L. Immunosuppressive effects of new 20-epi vitamin D3 analogues. Abstracts of 9th Workshop on Vitamin D, Orlando, Florida, p. 134, 1994.
5. Lillevang, S.T. Rosenkvist, J. Andersen, C. B. Larsen, S. Kemp, E. and Kris-tensen, T. Single and combined effects of the vitamin D analogue KH 1060 and cyclosporin A on mercuric chloride-induced autoimmune disease in the BN rat. Clin. Exp. Immunol. 88: 301-306, 1992.
6. Lemire, J.M. Immunomodulatory role of 1, 25-dihydroxyvitamin D3. J. Cell. Biochem. 49: 26-31, 1992.
7. Norman, A.W. Nemere, I. Zhou, L.X. Bishop, J.E. Lowe, K.E. Maiyar, A.C. Collins, E. Taoka, T. Sergeev, I. and Farach-Carson, M.C. l, 25(OH)2-vitamin D3 a steroid hormone that produces biological effects via both genomic and nongenomic pathways. J. Steroid Biochem. Mol. Biol. 41: 231-240, 1992.
8. Laiho, M. and Keski-Oja, J. Transforming growth factor-0: s as regulators of cellular growth and phenotype. CRC Crit. Rev. Oncogenesis, 3: 1-26, 1992.
9. Moses, H.L. Tucker, R.F. Leof, E.B. Coffey, R.J. Jr. Halper, J. and Shipley, G.D. Type-0 transforming growth factor is a growth stimulator and growth inhibitor. In: J. Feramisco, B. Ozanne, and C. Stiles (eds.), Cancer Cells, pp. 65-75. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1985.
10. Dickens, T.A. and Colletta, A.A. The pharmacological manipulation of members of the transforming growth factor-0 family in the chemoprevention of breast cancer. Bioessays, 75: 71-74, 1993.
11. Bower, M. Colston, K.W. Stein, R.C. Hedley, A. Gazet, J.C., Ford, H.T. and Coombes, R.C. Topical calcipotriol treatment in advanced breast cancer. Lancet, 337: 701-702, 1991.
12. Koli, K. and Keski-Oja, J. Vitamin D3 and calcipotriol enhance the secretion of transforming growth factor-01 and -β2 in cultured murine keratinocytes. Growth Factors, 8: 153-163, 1993.
13. Calverley, M.J. Synthesis of MC 903, a biologically active vitamin D analogue. Tetrahedron, 43: 4609-4619, 1987.
14. Binderup, L. Latini, S. Binderup, E. Bretting, C. Calverley, M. and Hansen, K. 20-Epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol. 42: 1569-1575, 1991.
15. Taipale, J. Koli, K. and Keski-Oja, J. Release of pericellular matrix-associated transforming growth factor-/ 1 of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J. Biol. Chem. 267: 25378-25384, 1992.
16. Taipale J. Lohi, J. Saarinen, J. Kovanen, P.T. Keski-Oja, J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-01 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem. 270: in press, 1995.
17. Miyazono, K. Hellman, U. Wernstedt, C. and Heldin, C.H. Latent high molecular weight complex of transforming growth factor-01: purification from human platelets and structural characterization. J. Biol. Chem. 263: 6407-6415, 1988.
18. Miyazono, K. Olofsson, A. Colosetti, P. and Heldin, C.H. A role of the latent TGF-01-binding protein in the assembly and secretion of TGF-01. EMBO J. 10: 1091-1101, 1991.
19. Laiho, M. DeCaprio, J.A. Ludlow, J.W. Livingston, D.M. and Massague\ J. Growth inhibition by TGF-/3 linked to suppression of retinoblastoma protein phosphorylation. Cell, 62: 175-185, 1990.
20. Brown, P.D. Wakefield, L.M. Levinson, A.D. and Sporn, M.B. Physiochemical activation of recombinant latent transforming growth factor-0s 1, 2, and 3. Growth Factors, 3: 35-43, 1990.
21. Taipale, J. Miyazono, K. Heldin, C.H. and Keski-Oja, J. Latent transforming growth factor-01 associates to fibroblast extracellular matrix via latent TGF-0 binding protein. J. Cell Biol. 124: 171-181, 1994.
22. Hedman, K. Kurkinen, M. Alitalo, K. Vaheri, A. Johansson, S. and Hook, M. Isolation of the pericellular matrix of human fibroblast cultures. J. Cell Biol. 81: 83-91, 1979.
23. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
24. Chomczynski, P. and Sacci, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159, 1987.
25. Sambrook, J. Fritsch, E.F. and Maniatis, T.E. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
26. Koli, K. Lohi, J. Hautanen, A. and Keski-Oja, J. Enhancement of vitronectin expression in human Hep. 2 hepatoma cells by transforming growth factor-01. Eur. J. Biochem. 199: 337-345, 1991.
27. Derynck, R. Jarret, J.A. Chen, E.Y. Eaton, D.H. Bell, J.R. Assoian, R.K. Roberts, A.B. Sporn, M.B. and Goeddel, D.V. Human transforming growth factor-0 complementary DNA sequence and expression in normal and transformed cells. Nature (Lond.), 316: 701-705, 1985.
28. Kanzaki, T. Olofsson, A. Mortn, A. Wernstedt, C. Hellman, U.K. Claesson-Welsh, L. and Heldin, C.H. TGF-01 binding protein: a component of the large latent TGF-01 with multiple repeat sequences. Cell, 61: 1051-1061, 1990.
29. Taipale, J. Matikainen, S. Hurme, M. Keski-Oja, J. Induction of transforming growth factor-01, its latent form binding protein and type II receptor expression during myeloid leukemia cell differentiation. Cell Growth & Differ. 5: 1309-1319, 1994.
30. Desprez, P.Y. Poujol, D. and Saez, S. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, E.C. 1.2.1.12.) gene expression in two malignant human mammary epithelial cell lines: BT-20 and MCF-7. Regulation of gene expression by 1, 25-dihydroxyvitamin D3 (l, 25-(OH)2D3). Cancer Lett. 64: 219-224, 1992.
31. Tucker, R.F. Shipley, G.D. Moses, H.L. and Holiey, R.W. Growth inhibitor from BSC-1 cells is closely related to the platelet typc-0 transforming growth factor. Science (Washington DC), 226: 705-707, 1984.
32. Koga, M. Eisman, J.A. and Sutherland, R.L. Regulation of epidermal growth factor receptor levels by 1, 25-dihydroxyvitamin D3 in human breast cancer cells. Cancer Res. 48: 2734-2739, 1988.
33. Wrana, J.L. Attisano, L. Wieser, R. Ventura, F. and Massague\ J. Mechanism of activation of the TGF-0 receptor. Nature (Lond.), 370: 341-347, 1994.
34. Lawrence, D.A. Pircher, R. and Julien, P. Conversion of a high molecular weight latent 0-TGF from chicken embryo fibroblasts into a low molecular weight active 0-TGF under acidic conditions. Biochem. Biophys. Res. Commun. 133: 1026-1034, 1985.
35. Lyons, R.M. Keski-Oja, J. and Moses, H.L. Proteolytic activation of latent transforming growth factor-0 from fibroblast-conditioned medium. J. Cell Biol. 106: 1659-1665, 1988.
36. Dallas, S.L. Park-Snyder, S. Miyazono, K. Twardzik, D. Mundy, G.R. and Bonewald, L.F. Characterization and autoregulation of latent transforming growth factor 0 (TGF0) complexes in osteoblast-like cell lines: production of a latent complex lacking the latent TGF0-binding protein. J. Biol. Chem. 269: 6815-6822, 1994.
37. Kojima, S. and Rifkin, D.B. Mechanism of retinoid-induced activation of latent transforming growth factor-0 in bovine endothelial cells. J. Cell. Physiol. 155: 323-332, 1993.
38. Knabbe, C. lippman, M.E. Wakefield, L.M. Flanders, K.C. Kasid, A. Derynck, R. and Dickson, R.B. Evidence that transforming growth factor-0 is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48: 417-428, 1987.
39. Glick, A.B. Flanders, K.C. Danielpour, D. Yuspa, S.H. and Sporn, M.B. Retinoic acid induces transforming growth factor-02 in cultured keratinocytes and mouse epidermis. Cell Regul. 1: 87-97, 1989.
40. Van Obberghen-Schilling, E. Roche, N.S. Flanders, K.C. Sporn, M.B. and Baker, C.C. Transforming growth factor-01 positively regulates its own expression in normal and transformed cells. J. Biol. Chem. 263: 7741-7746, 1988.
41. Bascom, C.C. Wolfshohl, J.R. Coffey, R.J.J. Madisen, L. Webb, N.R. Purchio, A.R. Derynck, R. and Moses, H.L. Complex regulation of transforming growth factor-01,-02, and-03 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factor-01 and-02. Mol. Cell. Biol. 9: 5508-5515, 1989.
42. Simboli-Campbell, M. and Welsh, J. Comparative effects of l, 25(OH)2D3 and EB1089 on cell cycle kinetics in MCF-7 cells. Abstracts of the 9th Workshop on Vitamin D, Orlando, Florida, p. 190, 1994.
43. Wakefield, L. Kim, S.J. Glick, A. Winokur, T. Colletta, A. and Sporn, M. Regulation of transforming growth factor subtypes by members of the steroid hormone superfamily. J. Cell Sci. Suppl. 13: 139-148, 1990.
44. Brelvi, Z.S. and Studzinski, G.P. Changes in the expression of oncogenes encoding nuclear phosphoproteins but not c-Ha-Ras have a relationship to monocytic differentiation of HL-60 cells. J. Cell Biol. 102: 2234-2243, 1986.
45. Oikawa, T. Hirotani, K. Ogasawara, H. Katayama, T. Nakamura, 0. Iwaguchi, T. and Hiragun, A. Inhibition of angiogenesis by vitamin D3 analogs. Eur. J. Pharmacol. 178: 247-250, 1990.
46. Welsh, J. Simboli-Campbell, M. and Tenniswood, M. Induction of apoptotic cell death by l, 25(OH)2D3 in MCF-7 breast cancer cells. Abstracts of 9th Workshop on Vitamin D, Orlando, Florida, p. 174, 1994.
47. Hansen, C.M. and Binderup, L. Effects of la25(OH)2D3 and some selected analogues on the invasive potential of human carcinoma cells in vitro. Abstracts of 9th Workshop on Vitamin D, Orlando, Florida, p. 20, 1994.
48. Koli, K. and Keski-Oja, J. Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes. J. Invest. Dermatol. 101: 706-712, 1993.
49. Lacraz, S. Dayer, J.M. Nicod, L. and Welgus, H.G. 1, 25-Dihydroxyvitamin D3 dissociates production of interstitial coUagenase and 92-kDa gelatinase in human mononuclear phagocytes. J. Biol. Chem. 269: 6485-6490, 1994.
50. Kragballe, K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J. Am. Acad. Dermatol. 27: 1001-1008, 1992.
51. Colston, K.W. Chander, S.K. Mackay, A.G. and Coombes, R.C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol. 44: 693-702, 1992.
52. Mor6n, A. Olofsson, A. Stenman, G. Sahlin, P. Kanzaki, T. Claesson-Welsh, L. ten Dijk, P. Miyazono, K. and Heldin, C.H. Identification and characterization of LTBP-2, a novel latent transforming growth factor-0 binding protein. J. Biol. Chem. 269: 32469-32478, 1994.